- Arvinas (New Haven, CT)
- …of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC ( R ) Discovery Engine platform to engineer proteolysis targeting chimeras, ... agreement for the development and commercialization of the clinical stage PROTAC ( R ) androgen receptor protein degrader ARV-766 for the treatment of prostate cancer.… more